|
|
CONTACT: Dr. John Gong, Managing Director, U.S. Operations; 301.540.5988 (o); HSRL, JOINN Forge Strategic Partnership Offering Broad Slate of Preclinical Services GERMANTOWN, MARYLAND (June 06, 2009) -- Confident they will provide a new level of service in an increasingly competitive global market for preclinical research, leaders from two labs on either side of the Pacific Ocean today announced their strategic partnership. Scientists at the two preclinical CROs -- Histo-Scientific Research Laboratories (HSRL) of Thurmont, MD., and JOINN Laboratories, a Beijing-based CRO with Washington DC-area office -- are now offering to pharmaceutical firms and drug developers a slate of preclinical services that produce sound research ready for submission to regulatory agencies around the world, including arguably the toughest: the U.S. Food and Drug Administration (US FDA). The alliance comes after several meetings at JOINN's Beijing headquarters, HSRL's Thurmont office and the latest annual meeting (March 2009) of The Society of Toxicology in Baltimore, Maryland. "We're really pleased JOINN has chosen us," said HSRL's Director of Pathology Dr. Serge Rousselle, DVM, ACVP. “Joinn has an impressive management team, a good reputation in the field and is therefore exactly the type of company we seek to support with our lineup of histopathology services. The collaboration will position both firms as strong competitors for contracts with drug companies seeking top-notch preclinical research strictly following GLP [Good Laboratory Practices],” Rousselle said. "This is a perfect fit for both sides," said Dr. John Gong, Joinn's Vice President, Chief Technology Officer and Managing Director of its U.S. Operations. Gong said he was impressed with HSRL's certified pathology services, extensive experience in toxicological pathology and tissue cross-reactivity studies and specialty techniques. Through their meetings and business interactions, scientists and officers from both companies have found that they share values of scientific integrity and a common goal of delivering high quality services and helping clients navigate the preclinical arena. This strategic alignment is positioning JOINN as a leader in preclinical research in Asia and represents a decisive step in expanding its global outreach. “Ultimately, John and I agreed that our firms' separate but common goals were better served through a joint mission of helping drug companies throughout the world bring safe, effective and affordable new medicines to market in a timely fashion,” Rousselle said. About HSRL: Histo-Scientific Research Laboratories (HSRL) is a full service, GLP- and OECD-compliant provider of histology and pathology services. HSRL was founded in 1998 as a histology laboratory by Tom Galati in the heart of Virginia’s Blue Ridge Mountains. In 2006 HSRL expanded into a full-service histopathology service company, adding a Thurmont, MD office, located in the Catoctin Mountain. Staffed with four experienced ACVP pathologists, HSRL also offers tissue cross-reactivity studies. The firm strives to offer quality and responsiveness at competitive prices. For more information, please visit http://www.hsrl.org/ About JOINN: Founded in 1995 in Beijing, China, JOINN Laboratories is a contract research organization (CRO) offering comprehensive services in all areas of preclinical drug development, from the early stage drug discovery to the late stage regulatory toxicology studies. JOINN USA serves its international clients with their new drug development programs, including their regulatory and technical requirements. JOINN’s mission is to earn and keep customers by providing timely, high-quality services in preclinical contract research at reasonable cost. For more information, please visit http://www.joinnlaboratories.com |
